Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Phenylpiperazine derivative, use method and uses thereof

An alkyl and drug technology, which is applied in the field of compounds and compositions for the treatment of central nervous system dysfunction of affective disorders, can solve the problems of delay and deterioration of SSRIs' therapeutic effect, and achieve good safety, stable properties and good clinical application prospects Effect

Active Publication Date: 2016-02-03
SUNSHINE LAKE PHARM CO LTD
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, clinical studies of depression have highlighted the lack of response to known SSRIs. Another factor that is often overlooked in antidepressant treatment is that the therapeutic effect of SSRIs is often delayed, sometimes during the first few weeks of treatment. will get worse
Additionally, sexual dysfunction is a common side effect of SSRIs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Phenylpiperazine derivative, use method and uses thereof
  • Phenylpiperazine derivative, use method and uses thereof
  • Phenylpiperazine derivative, use method and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0195] Example 12-(2-(piperazin-1-yl)phenoxy)nicotinamide

[0196]

[0197] Step 1) Synthesis of 4-(2-((3-carbamoylpyridin-2-yl)oxy)phenyl)piperazine-1-carboxylic acid tert-butyl ester

[0198] 4-(2-hydroxyphenyl)piperazine-1-carboxylic acid tert-butyl ester (0.42g, 1.51mmol), 2-chloronicotinamide (0.25g, 1.58mmol) and potassium carbonate (0.42g, 3.02mmol) were sequentially It was added into DMSO (10 mL), and then the reaction solution was heated to 110° C. for 20 hours. After the reaction, the reaction solution was cooled to room temperature, washed with water (20 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether / ethyl acetate (v / v)=2 / 1) to obtain the title compound as a pale yellow solid (0.42 g, 69.9%).

[0199] MS(ESI,pos.ion)m / z:399.1[M+H] + ;

[0200] 1 HNMR (CD...

Embodiment 2

[0205] Example 21-(2-((4-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)piperazine

[0206]

[0207] Step 1) Synthesis of 4-(2-((4-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)piperazine-1-carboxylic acid tert-butyl ester

[0208] The title compound of this step can be prepared by referring to the method described in step 1 of Example 1, that is, tert-butyl 4-(2-hydroxyphenyl)piperazine-1-carboxylate (0.42g, 1.51mmol), 2-chloro-4 -(trifluoromethyl)pyridine (0.29g, 1.58mmol) and potassium carbonate (0.42g, 3.02mmol) were reacted in DMSO (10mL) to prepare the crude product, which was purified by silica gel column (petroleum ether / ethyl acetate (v / v) = 2 / 1) to obtain the title compound as a pale yellow solid (0.25 g, 39.1%).

[0209] MS(ESI,pos.ion)m / z:424.1[M+H] + ;

[0210] 1 HNMR (CDCl 3 ,400MHz)δ(ppm):8.33(d,J=5.2Hz,1H),7.24-7.22(m,1H),7.19-7.16(m,2H),7.14-7.12(m,1H),7.07-7.04 (m,1H),6.95(m,1H),3.20-3.17(m,4H),2.93-2.91(m,4H),1.43(s,9H).

[0211] Step 2) Synthesis of 1-...

Embodiment 3

[0215] Example 31-(2-((5-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)piperazine

[0216]

[0217] Step 1) Synthesis of tert-butyl 4-(2-((5-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)piperazine-1-carboxylate

[0218] The title compound of this step can be prepared by referring to the method described in step 1 of Example 1, that is, tert-butyl 4-(2-hydroxyphenyl)piperazine-1-carboxylate (0.42g, 1.51mmol), 2-chloro-5 -(trifluoromethyl)pyridine (0.29g, 1.58mmol) and potassium carbonate (0.42g, 3.02mmol) were reacted in DMSO (10mL) to prepare the crude product, which was purified by silica gel column (petroleum ether / ethyl acetate (v / v)=2 / 1) the title compound was obtained as a white solid (0.35 g, 54.8%).

[0219] MS(ESI,pos.ion)m / z:424.1[M+H] + ;

[0220] 1 HNMR (CDCl 3 ,400MHz)δ(ppm):8.24(s,1H),7.85(dd,J=8.4,2.4Hz,1H),7.26-7.21(m,1H),7.15(dd,J=7.6,1.6Hz,1H ), 7.12(dd, J=7.2, 1.2Hz, 1H), 7.07-7.05(m, 1H), 6.87(d, J=8.8Hz, 1H), 3.25-3.23(m, 4H), 2.95-2.92( m,4H),1.44(s,9...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a phenylpiperazine derivative, a use method and uses thereof, and particularly relates to a class of novel (2-(heteroaryloxo)phenyl)piperazine derivatives and a pharmaceutical composition containing the compound, wherein the derivatives and the composition can be used for inhibiting 5-hydroxytryptamine reuptake. The present invention further relates to a method for preparing the compounds and the pharmaceutical composition, and uses of the compounds and the pharmaceutical composition in treatment of central nervous system dysfunction, particularly affective disorders.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to compounds and compositions for treating central nervous system dysfunction, especially affective disorders, as well as methods and uses thereof. In particular, described herein are phenylpiperazine derivatives that are useful as serotonin reuptake inhibitors. Background technique [0002] 5-HT (serotonin), a neurotransmitter that transmits signals in the brain and nervous system, plays a role in central nervous system (CNS) dysfunction, especially anxiety, depression, aggression and impulsive mood. play an important role. The five-serotonin transporter (5-HTtransporter, 5-HTT / serotonintransporter, SERT) is a transmembrane transporter with high affinity for 5-HT, which reuptakes five-serotonin from the synaptic gap into the presynaptic neuron, directly Affects the concentration of serotonin in the synaptic cleft. [0003] Historically, pharmacological treatment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D213/87C07D213/643C07D213/85C07D277/56A61K31/496A61P25/24A61P25/22A61P25/00A61P25/18A61P25/20A61P25/14A61P25/16A61P25/30A61P15/00A61P21/00A61P19/00
CPCC07D213/643C07D213/85C07D213/87C07D277/56
Inventor 金传飞梁海平张英俊张霁亢宁李勇刘言萍
Owner SUNSHINE LAKE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com